Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 27,734 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

ALK33-001: A Study of RDC-0313 Administered to Healthy Adults

NCT00800319
View directory record Official record
Conditions
Alcohol Dependence
Interventions
RDC-0313, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MonaLisa Touch Randomized Double-Blind Placebo Controlled Study

NCT03331328
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause
Interventions
MonaLisa Touch
Device
Lead sponsor
Michigan Institution of Women's Health PC
Other
Eligibility
Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699

NCT03953092
View directory record Official record
Conditions
Diabete Mellitus
Interventions
YG1699, Placebos
Drug
Lead sponsor
Youngene Therapeutics Inc., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 8, 2026, 10:54 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

NCT07772492
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Meridian, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

NCT05948592
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
TP-102, Placebo
Biological · Other
Lead sponsor
Technophage, SA
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

NCT02990793
View directory record Official record
Conditions
PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms
Interventions
Active MeRT Treatment, Sham MeRT Treatment
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Costa Mesa, California • Long Beach, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

NCT02201849
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Study Drug, Active Control, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Colchicine and CRP in Atrial Fibrillation and AF Ablation

NCT01755949
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Colchicine, 0.6 mg PO BID, Matching placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder

NCT03787628
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol (CBD) 600 mg, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tarzana, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 1Phase 2 Interventional

A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder

NCT00593099
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

NCT01556763
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions
EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

NCT00656487
View directory record Official record
Conditions
Cannabis Dependence, Cannabis Withdrawal
Interventions
rimonabant, placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
21 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

NCT02715193
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Diabetes
Interventions
REMD-477, Placebo Comparator
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

NCT00842816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ST101, Placebo
Drug
Lead sponsor
Sonexa Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

NCT04199104
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Fresno, California • San Marcos, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

NCT03064438
View directory record Official record
Conditions
Acne Rosacea
Interventions
ACCU-D1, Vehicle
Drug
Lead sponsor
Accuitis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Louisville, Kentucky • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults

NCT00746798
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Anaheim, California • Colorado Springs, Colorado • South Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 8, 2026, 10:54 AM EDT
Not listed Phase 3 Interventional

NB-001 Treatment of Recurrent Herpes Labialis

NCT01695187
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001 (0.3%), Placebo
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 8, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

NCT03672604
View directory record Official record
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
NLY01
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 8, 2026, 10:54 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

NCT07614984
View directory record Official record
Conditions
Lipoprotein(a)
Interventions
MK-7262, Enlicitide, Placebo for MK-7262, Placebo for enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Alexander City, Alabama • Mobile, Alabama • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 8, 2026, 10:54 AM EDT